Floatz logo

Alvespimycin

Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity cohort.

Asset / SponsorPhaseRating
Cetuximab
Fox Chase Cancer Center
Phase 1/2B
Irinotecan
AIDS Malignancy Consortium
Phase 1/2B
Everolimus
Fox Chase Cancer Center
Phase 1CC
7-hydroxystaurosporine
National Cancer Institute (NCI)
Phase 1CC
(11-L-THREONINE, 29-L-ARGININE)LACTOFERRIN(HUMAN) PRODUCED BY ASPERGILLUS NIGER VAR. AWAMORI
Stanford University
Phase 1CC
Carboplatin
AIDS Malignancy Consortium
Phase 1CC
Vorinostat
AIDS Malignancy Consortium
Phase 1CC
Gefetinib
National Cancer Institute (NCI)
N/AD

Same molecule, other indications

Alvespimycin is also rated in:

cancer of unknown primary siteDormant
CCC
Indicative ·
52 / 100
View asset →
salivary gland adenoid cystic carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
Stage IV Adult Diffuse Small Cleaved Cell LymphomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →